ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0316

Exploring Alternative Responder Definitions for EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) for Use in Sjögren’s Clinical Trials

Samantha Wratten1, Linda Abetz-Webb2, Ethan Arenson2, Mike Greenwood2, Rebecca Hall3, Pip Griffiths4, Simon J Bowman5, Wolfgang Hueber6, Briana Ndife7, Daniel Kuessner6 and Pushpendra Goswami6, 1Adelphi Values, Macclesfield, United Kingdom, 2Adelphi Values, Bollington, United Kingdom, 3Adelphi Values Ltd, Bollington, United Kingdom, 4Former Adelphi Values, Bollington, United Kingdom, 5Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis, East Hanover, NJ

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, Measurement Instrument, Sjögren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Sjögren’s is a chronic autoimmune disease symptomatically characterized by dryness, pain and fatigue, which are typically assessed in clinical trials using EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI). However high placebo response rates are observed when responder definition guidelines (ESSPRI score ≤5 and improvement of ≥1-point or ≥15%) are implemented. The aim of this study was to explore possible options for alternative responder definitions that indicate the optimal balance of sensitivity (the ability to correctly identify improved patients) and specificity (the ability to correctly identify stable patients) to reduce possible misclassification of patients in Sjögren’s clinical trial analyses.

Methods: Thresholds for alternative responder definitions were derived using blinded data from a Phase 2b randomized, double-blind, placebo-controlled, multicenter, parallel-group trial (NCT02962895) in primary Sjögren’s (n=190 at Week 24) and were validated using blinded pooled data from three Phase 2 randomized, double-blind, placebo-controlled, parallel studies (NCT02775916; NCT02291029; NCT02149420) in primary Sjögren’s (n=116 at Week 12; n=68 at Week 24).

Anchor- and distribution-based methods were conducted and triangulated to derive thresholds for an alternative responder definition based on a minimal symptom severity threshold and a more conservative minimal meaningful improvement threshold. A range of anchors were included in the anchor-based analyses based on suitable correlations with ESSPRI ( >0.30), including Patient Global Assessment (PaGA), Physician Global Assessment (PhGA), Short Form-36 (SF-36) physical component score (PCS) and mental component score (MCS; validation analyses only), Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F; derivation analyses only), and Multidimensional Fatigue Inventory (MFI; validation analyses only).

Results: Both analysis populations were predominantly female ( >90%), white (90%), and with a mean age of 50 years (range: 20-75). A realistic meaningful change threshold range between 1- and 2-points was identified through derivation analysis; ROC estimates and correlation weighted minimal important mean change supported a minimal threshold of 1.5-1.6 for ESSPRI total score. Correlation weighted mean change estimates and upper 95% confidence intervals supported a more conservative value of 2 or more. The minimal symptom severity threshold range was between 3.0 and 5.3, however 3 or less showed the greatest sensitivity and specificity. Validation analyses generally supported the threshold ranges suggested by the derivation analyses, with a meaningful change threshold range of 1.46-2.11 and a minimal symptom severity range of 2.7 to 4.0 based on the most suitable anchors (PaGA and PhGA).

Conclusion: The results of these analyses suggest that an alternative, more conservative composite ESSPRI responder definition could be used in future trials: an ESSPRI score of ≤3 and an improvement in ESSPRI score of 1.5-points or more. Further analysis in unblinded data is warranted to further test the utility of this new endpoint.


Disclosures: S. Wratten, None; L. Abetz-Webb, None; E. Arenson, None; M. Greenwood, Adelphi Group, 3; R. Hall, None; P. Griffiths, None; S. Bowman, Novartis, 1, 2, Astrazeneca, 2, Biogen, 2, BMS, 2, Celgene, 2, Medimmune, 2, MTPharma, 2, Ono, 2, UCB, 2, xtlbio, 2; W. Hueber, Novartis, 3, 11; B. Ndife, Novartis, 3, 11; D. Kuessner, Novartis Pharma AG, 3, 11; P. Goswami, Novartis Pharma AG, 3.

To cite this abstract in AMA style:

Wratten S, Abetz-Webb L, Arenson E, Greenwood M, Hall R, Griffiths P, Bowman S, Hueber W, Ndife B, Kuessner D, Goswami P. Exploring Alternative Responder Definitions for EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) for Use in Sjögren’s Clinical Trials [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/exploring-alternative-responder-definitions-for-eular-sjogrens-syndrome-patient-reported-index-esspri-for-use-in-sjogrens-clinical-trials/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploring-alternative-responder-definitions-for-eular-sjogrens-syndrome-patient-reported-index-esspri-for-use-in-sjogrens-clinical-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences